Hong Sun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hong Sun has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Alexander J. Mentzer
Centre for Human Genetics Oxford England University of Oxford
1 shared publication - Ana Tomás
Unidade de Investigação em Patobiologia Molecular, Instituto Português de Oncologia de Lisboa Francisco Gentil E.P.E., Lisboa, Portugal
1 shared publication - Andrew D. Davidson
School of Cellular and Molecular Medicine, University of Bristol, Bristol, UK
1 shared publication - Andrew J. McMichael
Centre for Immuno-Oncology, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom
1 shared publication - Bas W. A. Peeters
Nuffield Department of Medicine, University of Oxford, Oxford, UK
1 shared publication Beibei Wang
Chinese Academy of Medical Sciences Oxford Institute, Old Road Campus, Oxford, UK
1 shared publication
Latest Publications
- 30 June 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 8 (84) , eabl8881
HLA-E–restricted SARS-CoV-2–specific T cells from convalescent COVID-19 patients suppress virus replication despite HLA class Ia down-regulation
Pathogen-specific CD8 + T cell responses restricted by the nonpolymorphic nonclassical class Ib molecule human leukocyte antigen E (HLA-E) are rarely reported in viral infections. The natural HLA-E ligand is a signal peptide derived from classical class Ia HLA molecules that interact with the NKG2/CD94 receptors to regulate natural killer cell functions, but pathogen-derived peptides can also be presented by HLA-E. Here, we describe five peptides from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that elicited HLA-E–restricted CD8 + T cell responses in convalescent patients with coronavirus disease 2019. These T cell responses were identified in the blood at frequencies similar to those reported for classical HLA-Ia–restricted anti–SARS-CoV-2 CD8 + T cells. HLA-E peptide–specific CD8 + T cell clones, which expressed diverse T cell receptors, suppressed SARS-CoV-2 replication in Calu-3 human lung epithelial cells. SARS-CoV-2 infection markedly down-regulated classical HLA class I expression in Calu-3 cells and primary reconstituted human airway epithelial cells, whereas HLA-E expression was not affected, enabling T cell recognition. Thus, HLA-E–restricted T cells could contribute to the control of SARS-CoV-2 infection alongside classical T cells.
- 30 June 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 8 (84) , eabl8881
HLA-E–restricted SARS-CoV-2–specific T cells from convalescent COVID-19 patients suppress virus replication despite HLA class Ia down-regulation
Pathogen-specific CD8 + T cell responses restricted by the nonpolymorphic nonclassical class Ib molecule human leukocyte antigen E (HLA-E) are rarely reported in viral infections. The natural HLA-E ligand is a signal peptide derived from classical class Ia HLA molecules that interact with the NKG2/CD94 receptors to regulate natural killer cell functions, but pathogen-derived peptides can also be presented by HLA-E. Here, we describe five peptides from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that elicited HLA-E–restricted CD8 + T cell responses in convalescent patients with coronavirus disease 2019. These T cell responses were identified in the blood at frequencies similar to those reported for classical HLA-Ia–restricted anti–SARS-CoV-2 CD8 + T cells. HLA-E peptide–specific CD8 + T cell clones, which expressed diverse T cell receptors, suppressed SARS-CoV-2 replication in Calu-3 human lung epithelial cells. SARS-CoV-2 infection markedly down-regulated classical HLA class I expression in Calu-3 cells and primary reconstituted human airway epithelial cells, whereas HLA-E expression was not affected, enabling T cell recognition. Thus, HLA-E–restricted T cells could contribute to the control of SARS-CoV-2 infection alongside classical T cells.